Arcus Biosciences Stock Fundamentals
| RCUS Stock | USD 9.34 0.20 2.10% |
Arcus Biosciences fundamentals help investors to digest information that contributes to Arcus Biosciences' financial success or failures. It also enables traders to predict the movement of Arcus Stock. The fundamental analysis module provides a way to measure Arcus Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arcus Biosciences stock.
At this time, Arcus Biosciences' Total Operating Expenses is comparatively stable compared to the past year. Total Other Income Expense Net is likely to gain to about 49.4 M in 2025, whereas Selling General Administrative is likely to drop slightly above 61.9 M in 2025. Arcus | Select Account or Indicator |
Arcus Biosciences Company Return On Equity Analysis
Arcus Biosciences' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Arcus Biosciences Return On Equity | -0.6 |
Most of Arcus Biosciences' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arcus Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Arcus Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Arcus Biosciences has a Return On Equity of -0.5977. This is 97.51% lower than that of the Biotechnology sector and 98.36% lower than that of the Health Care industry. The return on equity for all United States stocks is 92.81% higher than that of the company.
Arcus Biosciences Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Arcus Biosciences's current stock value. Our valuation model uses many indicators to compare Arcus Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arcus Biosciences competition to find correlations between indicators driving Arcus Biosciences's intrinsic value. More Info.Arcus Biosciences is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Arcus Biosciences' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Arcus Biosciences by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Arcus Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcus Biosciences' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcus Biosciences could also be used in its relative valuation, which is a method of valuing Arcus Biosciences by comparing valuation metrics of similar companies.Arcus Biosciences is currently under evaluation in return on equity category among its peers.
Arcus Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcus Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcus Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Arcus Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.10) % | ||||
| Operating Margin | (3.96) % | ||||
| Current Valuation | 108.66 M | ||||
| Shares Outstanding | 105.84 M | ||||
| Shares Owned By Insiders | 5.51 % | ||||
| Shares Owned By Institutions | 83.46 % | ||||
| Number Of Shares Shorted | 6.88 M | ||||
| Price To Earning | 27.69 X | ||||
| Price To Book | 2.12 X | ||||
| Price To Sales | 3.91 X | ||||
| Revenue | 258 M | ||||
| Gross Profit | (190 M) | ||||
| EBITDA | (269 M) | ||||
| Net Income | (283 M) | ||||
| Cash And Equivalents | 1.05 B | ||||
| Cash Per Share | 14.48 X | ||||
| Total Debt | 48 M | ||||
| Debt To Equity | 0.17 % | ||||
| Current Ratio | 6.22 X | ||||
| Book Value Per Share | 5.26 X | ||||
| Cash Flow From Operations | (170 M) | ||||
| Short Ratio | 5.86 X | ||||
| Earnings Per Share | (3.14) X | ||||
| Target Price | 32.55 | ||||
| Number Of Employees | 627 | ||||
| Beta | 1.36 | ||||
| Market Capitalization | 1.01 B | ||||
| Total Asset | 1.15 B | ||||
| Retained Earnings | (1.13 B) | ||||
| Working Capital | 790 M | ||||
| Net Asset | 1.15 B |
About Arcus Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcus Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcus Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcus Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 85 M | 64.3 M | |
| Total Revenue | 258 M | 270.9 M | |
| Cost Of Revenue | 391 M | 410.6 M | |
| Stock Based Compensation To Revenue | 0.29 | 0.34 | |
| Sales General And Administrative To Revenue | 0.53 | 0.51 | |
| Research And Ddevelopement To Revenue | 1.74 | 1.65 | |
| Capex To Revenue | 0.02 | 0.02 | |
| Revenue Per Share | 2.86 | 3.01 | |
| Ebit Per Revenue | (1.28) | (1.34) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.